mTOR在膀胱癌治疗中的研究进展  

Research Progress of mTOR in Treatment of Bladder Cancer

作　　者：曾繁浩 雷容 张克 李祥孟 夏成兴 颜汝平[1] ZENG Fanhao;LEI Rong;ZHANG Ke;LI Xiangmeng;XIA Chengxing;YAN Ruping(Department of Urology,6he Secood Afiliated Hospital of Kunming Medical University,Kunming 650101,China)

机构地区：[1]昆明医科大学第二附属医院泌尿外科,昆明650101

出　　处：《医学综述》2021年第8期1523-1527,1533,共6页Medical Recapitulate

基　　金：国家自然科学基金(81860453);云南省医疗卫生单位内设研究机构科研项目(2018NS0304);云南省高新技术产业发展项目计划(云高新产业发展201601)。

摘　　要：哺乳动物雷帕霉素靶蛋白(mTOR)及其相关通路作为膀胱癌治疗的新靶点之一,正逐渐受到关注。作用于mTOR靶点,可诱导膀胱癌细胞发生凋亡、自噬以及干扰细胞周期对膀胱癌起到治疗作用,同时具有安全、不良反应少、高效且不易继发耐药等优点。但目前利用该靶点治疗膀胱癌的作用机制研究大多只是靶向于单一通路或靶点,其疗效尚不令人满意。而膀胱癌等肿瘤性疾病属于异质性疾病,其发病机制往往涉及多条通路。因此,若将与mTOR靶点相关的两条或以上通路整合在一起,开启多通路治疗膀胱癌,将大大提高膀胱癌的治疗效果,改善患者预后。Mammalian target of rapamycin(mTOR)and its related pathways have been drawing more and more attention as a new target for the treatment of bladder cancer.By acting on mTOR target,it can induce apoptosis,autophagy and interfere with cell cycle,thus playing a therapeutic role in bladder cancer.Meanwhile,it has the advantages of good safety,less adverse reactions,high efficiency and less drug resistance.However,most of the current studies on the mechanism of using this target in the treatment of bladder cancer only target a single pathway or target,and the efficacy is not satisfactory.Tumor diseases,such as bladder cancer,belong to heterogeneous diseases,and their pathogenesis often involves multiple pathways.Therefore,if two or more pathways related to mTOR targets are integrated together to open the era of multi-pathway treatment for bladder cancer,the therapeutic effect will be greatly improved and the prognosis of the patients will be improved.

关 键 词：膀胱癌 哺乳动物雷帕霉素靶蛋白 自噬 细胞凋亡 

分 类 号：R737.14[医药卫生—肿瘤]